8-甲氧基-1.2.3.4-四氢萘-2-胺 | 3880-77-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 8-甲氧基-1.2.3.4-四氢萘-2-胺
• 英文名称: 8-methoxy-2-aminotetralin
• 英文别名: 7-amino-1-methoxy-5,6,7,8-tetra-hydro-naphthalene；SKF 88254；2-amino-8-methoxy-1,2,3,4-tetrahydronaphthalene；2-amino-8-methoxytetralin；8-Methoxy-1,2,3,4-tetrahydro-2-naphthylamin；8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine
• CAS: 3880-77-1
• 化学式: C₁₁H₁₅NO
• mdl: MFCD00906373
• 分子量: 177.246
• InChiKey: RVKOHSCTEHZRRT-UHFFFAOYSA-N

物化性质

• 沸点：
  309.1±42.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-甲氧基-1.2.3.4-四氢萘-2-胺 在 氢溴酸 作用下， 反应 2.0h， 以74.3%的产率得到2-amino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide
  参考文献：
  名称：

  构象限制和构象定义的酪胺类似物是苯乙醇胺N-甲基转移酶的抑制剂。

  摘要：

  在寻找肾上腺素合成酶苯基乙醇胺N-甲基转移酶（PNMT; EC 2.1.1.28）的选择性抑制剂，酚2-氨基四氢化萘（酪胺的构象受限类似物为12-15）和酚苯并双环[3.2.1]辛胺（使用22-24作为酪胺的构象定义类似物）来获得有关天然底物去甲肾上腺素在PNMT活性位点上的儿茶酚羟基的结合相互作用的信息。另外，这些类似物提供了有关构象柔性对酚性苯基乙胺中氨基乙基侧链的活性位相互作用的影响的信息，这可能有助于学习去甲肾上腺素在PNMT活性位点结合的方式。类似物22-24通过九步序列合成，其中，Friedel-Crafts型分子内环化是苯并双环[3.2.1]辛烷骨架构建的关键步骤。对-酪胺（10，Ki = 294 microM）比苯乙胺（1，Ki = 854 microM）更有效，但间-酪胺（9，Ki = 1250 microM）比苯基乙胺（作为PNMT抑制剂）的效力更弱。同样，在构象受限和

  DOI：

  10.1021/jm00122a032
• 作为产物：
  描述：

  在 platinum(IV) oxide 、 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 45.0 ℃ 、303.98 kPa 条件下， 反应 3.5h， 生成 8-甲氧基-1.2.3.4-四氢萘-2-胺
  参考文献：
  名称：

  2-Amido-8-methoxytetralins: A series of nonindolic melatonin-like agents

  摘要：

  A series of unsubstituted and methoxy-substituted 2-amidotetralins (4a-q) was prepared and evaluated for their ability to compete for 2-[I-125]iodomelatonin binding to chicken retinal membranes and for their potency to inhibit the calcium-dependent release of [H-3]dopamine from rabbit retina. The lead compound, 2-acetamido-8-methoxytetralin (4j), showed a moderate affinity (K(i) = 46 nM) and potency (IC50 = 1.4 nM) at the melatonin receptor. The structural requirements necessary for optimal agonistic activity at the melatonin receptor are as follows. First, the amido group, which should have a small, nonbranched alkyl group, is essential for affinity, and second, the methoxy substituent at the 8-position of the 2-amidotetralin ring is essential for optimal agonistic activity at the melatonin receptor. We concluded that this series of unsubstituted and methoxy-substituted 2-amidotetralins constitutes a class of nonindolic melatonin-like agents that can be used as pharmacological tools to further characterize melatonin receptors and to elucidate the mode of action of melatonin.

  DOI：

  10.1021/jm00072a008

文献信息

• [EN] PYRIMIDINE AMIDE COMPOUNDS<br/>[FR] COMPOSÉS PYRIMIDINE AMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012123467A1

  公开（公告）日：2012-09-20

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的化合物为式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，例如哮喘和慢性阻塞性肺病（COPD）等，具有实用性。
• Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, processes
  申请人：Bayer Aktiengesellschaft

  公开号：US04868331A1

  公开（公告）日：1989-09-19

  Antithrombotic, antiatherosclerotic and antiischaemic compounds of the formula ##STR1## in which R.sup.1 is ##STR2## or SO.sub.2 R.sup.4, R.sup.3 is aryl, substituted aryl, heteroaryl, aralkyl or the group ##STR3## R.sup.4 is aryl or substituted aryl, R.sup.2 is OH, alkoxy, phenoxy, benzoxy or NR.sup.5 R.sup.6, and R.sup.5 and R.sup.6 each independently is hydrogen or alkyl, or one of the radicals R.sup.5 or R.sup.6 is benzyl, and physiologically acceptable salts thereof with mono- and divalent cations.

  公式为##STR1##的抗血栓、抗动脉粥样硬化和抗缺血化合物，其中R.sup.1是##STR2##或SO.sub.2R.sup.4，R.sup.3是芳基、取代芳基、杂环芳基、芳基烷基或基团##STR3##，R.sup.4是芳基或取代芳基，R.sup.2是OH、烷氧基、苯氧基、苯甲氧基或NR.sup.5R.sup.6，R.sup.5和R.sup.6各自独立地是氢或烷基，或者其中的一个基团R.sup.5或R.sup.6是苄基，以及其与一价和二价阳离子形成的生理上可接受的盐。
• PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Hu Essa

  公开号：US20090062291A1

  公开（公告）日：2009-03-05

  The present invention is directed to compounds, useful as PDE10 inhibitors, having the formula where R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及化合物，其具有式，可用作PDE10抑制剂，其中R1、R2、R3、R4、X、Y和Z的定义如本文所述，以及含有此类化合物的制药组合物和制备此类化合物的过程。本发明还涉及治疗由PDE10介导的疾病的方法，例如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相障碍、强迫症等。
• Novel aminotransferase, gene encoding the same, and method of using them
  申请人：Ito Noriyuki

  公开号：US20100285544A1

  公开（公告）日：2010-11-11

  The invention relates to a novel aminotransferase, DNA encoding the enzyme, a recombinant vector into which the DNA has been introduced, and a transformant into which the vector has been introduced. Further, the invention also relates to a method for producing an optically active amino compound utilizing the enzyme or transformant. The aminotransferase of the invention has an ability of efficiently converting a ketone compound, particularly a cyclic ketone compound to an optically active amino compound. According to the invention, a method for efficiently producing an optically active amino compound, particularly an optically active cyclic amino compound is provided.

  本发明涉及一种新型氨基转移酶、编码该酶的DNA、已引入该DNA的重组载体以及已引入该载体的转化菌株。此外，本发明还涉及一种利用该酶或转化菌株生产光学活性氨基化合物的方法。本发明的氨基转移酶能够高效地将酮类化合物，尤其是环状酮类化合物转化为光学活性氨基化合物。根据本发明，提供了一种高效生产光学活性氨基化合物，尤其是光学活性环状氨基化合物的方法。
• Substituted 2-amidotetralins as melatonin agonists and antagonists
  申请人：Northwestern University

  公开号：US05151446A1

  公开（公告）日：1992-09-29

  The present invention relates generally to compounds having melatonin receptor activities and in particular to substituted 2-amidotetralin derivatives; to pharmaceutical preparations comprising such compounds; and to methods for using these compounds as therapeutic and diagnostic reagents.

  本发明涉及具有褪黑激素受体活性的化合物，特别是取代的2-氨基四氢萘衍生物；包括含有这种化合物的药物制剂；以及使用这些化合物作为治疗和诊断试剂的方法。